Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer

被引:22
|
作者
Okamura, Masako [2 ]
Akizuki, Nobuya [1 ]
Nakano, Tomohito [2 ]
Shimizu, Ken [2 ]
Ito, Tatsuhiko [1 ]
Akechi, Tatsuo [3 ]
Uchitomi, Yosuke [1 ]
机构
[1] Natl Canc Ctr Hosp E, Psychooncol Div, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr, Div Psychiat, Chuo Ku, Tokyo 1040045, Japan
[3] Nagoya City Univ, Sch Med, Dept Psychiat, Mizuho Ku, Nagoya, Aichi 4678601, Japan
关键词
algorithm; major depressive disorder; advanced cancer; antidepressant; clinical experience;
D O I
10.1002/pon.1213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective of this study was to describe the applicability and the dropout of the pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychiatrists treated major depressive disorder in advanced cancer patients on the basis of the algorithm. For discussing the problems related to the algorithm, we reviewed the reasons for the non-application of the algorithm and the reasons for dropout of patients within a week of initiation of treatment. The algorithm was applied in 54 of 59 cases (applicability rate, 92%). The reasons for the non-application of the algorithm were as follows: the need to add a benzodiazepine to an antidepressant in 4 cases and the need to choose alprazolam despite the depression being moderate in severity, in order to obtain a rapid onset action and reduce anxiety in a patient with short prognosis. Nineteen of the 55 patients dropped out within a week of initiation of treatment based on the algorithm. Delirium was the most frequent reason for dropout. The applicability rate was high, but several problems were identified, including those related to the combination of antidepressants and benzodiazepines, pharmacological treatment of depression in patients with short prognosis, and delirium due to antidepressants. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:154 / 160
页数:7
相关论文
共 50 条
  • [11] Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review
    Cao, Bing
    Zhu, Judy
    Zuckerman, Hannah
    Rosenblat, Joshua D.
    Brietzke, Elisa
    Pan, Zihang
    Subramanieapillai, Mehala
    Park, Caroline
    Lee, Yena
    McIntyre, Roger S.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2019, 92 : 109 - 117
  • [12] Use of Risperidone as Augmentation Treatment for Major Depressive Disorder
    Owenby, Ryan K.
    Brown, Lindsey T.
    Brown, Jamie N.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (01) : 95 - 100
  • [13] Evidence for the use of vilazodone in the treatment of major depressive disorder
    Reinhold, Jennifer A.
    Mandos, Laura A.
    Lohoff, Falk W.
    Rickels, Karl
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (15) : 2215 - 2224
  • [14] The use of quetiapine in the treatment of major depressive disorder: Evidence from clinical and experimental studies
    Ignacio, Zuleide Maria
    Calixto, Ana Valquiria
    da Silva, Ritele Hernandez
    Quevedo, Joao
    Reus, Gislaine Zilli
    NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2018, 86 : 36 - 50
  • [15] Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
    Fabbri, Chiara
    Montgomery, Stuart
    Lewis, Cathryn M.
    Serretti, Alessandro
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2020, 35 (05) : 233 - 242
  • [16] Clinical review of treatment options for major depressive disorder in patients with coronary heart disease
    Alosaimi, Fahad D.
    Baker, Brian
    SAUDI MEDICAL JOURNAL, 2012, 33 (11) : 1159 - 1168
  • [17] Psychopharmacologic treatment of pediatric major depressive disorder
    Boylan, Khrista
    Romero, Soledad
    Birmaher, Boris
    PSYCHOPHARMACOLOGY, 2007, 191 (01) : 27 - 38
  • [18] Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
    Alvarez, Enric
    Perez, Victor
    Artigas, Francesc
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 1297 - 1307
  • [19] The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder
    Sahli, Zeyad T.
    Banerjee, Pradeep
    Tarazi, Frank I.
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (05) : 515 - 523
  • [20] Treatment outcomes in major depressive disorder in patients with comorbid alcohol use disorder: A STAR*D analysis
    Tang, Victor M.
    Yu, Dengdeng
    Weissman, Cory R.
    Jones, Brett D. M.
    Wang, Guan
    Sloan, Matthew E.
    Blumberger, Daniel M.
    Daskalakis, Zafiris J.
    Le Foll, Bernard
    Voineskos, Daphne
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 339 : 691 - 697